title: Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
abstract: Brentuximab Vedotin is an antibody - drug conjugate targeting CD30. We report a case of severe cytokine release syndrome (CRS) after administration of the first dose of Brentuximab Vedotin in a 64-yr-old patient with relapsed systemic anaplastic large cell lymphoma (sALCL). To our knowledge, this is the first case of CRS to Brentuximab Vedotin described in the literature. However, CRS to Brentuximab Vedotin might be underestimated, as the drug has not been tested in large phase III trials yet.
authors.affiliation: Department of Medicine III, Medical Centre of the University of Munich, Munich, Germany.
authors.forename: Stefan K
authors.initials: SK
authors.lastname: Alig
authors.affiliation: Department of Medicine III, Medical Centre of the University of Munich, Munich, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Dreyling
authors.affiliation: Department of Medicine III, Medical Centre of the University of Munich, Munich, Germany.
authors.forename: Bettina
authors.initials: B
authors.lastname: Seppi
authors.affiliation: Department of Medicine II, Medical Centre of the University of Munich, Munich, Germany.
authors.forename: Benedikt
authors.initials: B
authors.lastname: Aulinger
authors.affiliation: Department of Medicine III, Medical Centre of the University of Munich, Munich, Germany.
authors.forename: Lukas
authors.initials: L
authors.lastname: Witkowski
authors.affiliation: Department of Medicine III, Medical Centre of the University of Munich, Munich, Germany.
authors.forename: Christina T
authors.initials: CT
authors.lastname: Rieger
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000079963:Brentuximab Vedotin; D003520:Cyclophosphamide / Q000627:therapeutic use; D016207:Cytokines / Q000378:metabolism*; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage* / Q000009:adverse effects*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011239:Prednisolone / Q000627:therapeutic use; D012074:Remission Induction; D013577:Syndrome; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D016207:Cytokines; D018796:Immunoconjugates; D014750:Vincristine; D005047:Etoposide; D000079963:Brentuximab Vedotin; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone
keywords: Brentuximab Vedotin; CD30; anaplastic large cell lymphoma; cytokine release syndrome; infusion reaction